Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Gaceta mexicana de oncología
versión On-line ISSN 2565-005Xversión impresa ISSN 1665-9201
Resumen
ESCUDERO-ACHA, Patricia; PENASCO, Yhivian y GONZALEZ-CASTRO, Alejandro. Paclitaxel-induced pneumonitis. Review of the literature. Gac. mex. oncol. [online]. 2020, vol.19, n.1, pp.33-39. Epub 30-Abr-2021. ISSN 2565-005X. https://doi.org/10.24875/j.gamo.19000318.
Introduction:
Knowledge of the toxicity of anticancer drugs is crucial in the management of the cancer patient. We present a review of the medical bibliography regarding paclitaxel-induced pneumonitis in order to analyze the available diagnostic options, therapeutic possibilities and the prognosis of these patients
Methods:
A computerized search of Medline, PubMed, and Web of knowledge was carried out. The following keywords were searched within the title: taxane,” paclitaxel” and pneumonitis.” Patients were classified as survivors or dead. A descriptive and comparative analysis was performed
Results:
A total of 51 clinical cases of patients who developed paclitaxel-induced pneumonitis were obtained. The neoplasms treated in order of frequency were: breast (35%), lung (25%), gastric (21.5%), pancreas (10%) and lymphoma (4%). The time since the last dose of paclitaxel received and diagnosis of pneumonitis was documented in 57% of cases, with an average latency of 208 ± 174 h. The need for invasive mechanical ventilation and therapy with intravenous corticoid bolus were associated with variable mortality of the patients (p < 0.05)
Conclusions:
Paclitaxel-induced pneumonitis is a potentially serious entity. It is necessary to deepen the development of diagnostic and therapeutic protocols that improve the prognosis in severe cases.
Palabras llave : Pneumonitis; Paclitaxel; Taxanes.